Managing Director and Senior Biotechnology Analyst
Simos Simeonidis, Ph.D., is a Managing Director and Senior Biotechnology Analyst. Dr. Simeonidis joined Rodman from First Albany Capital where he was a Vice President and Senior Biotechnology Analyst covering the small and mid-cap biotechnology and specialty pharmaceuticals sector. Prior to First Albany Capital, Dr. Simeonidis was an associate biotechnology analyst at Morgan Stanley and before that, he was an Associate Director in the Business Development/Licensing and Strategic Planning groups at Novartis. Dr. Simeonidis also brings additional industry experience through his tenure at GlaxoSmithKline’s Global Commercial Strategy group.
Prior to his role as a research analyst, Dr. Simeonidis was a faculty member at Harvard Medical School and the Beth Israel Deaconess Medical Center. His work on the transcriptional regulation of gene expression through the NF-kB/IkB pathway and in signal transduction in cancer, inflammation and infectious disease led to grant awards and numerous articles in leading peer-reviewed biomedical journals. He has presented his work at leading medical and scientific conferences and has held academic appointments at Columbia University, Northeastern Illinois University and Boston College.
Dr. Simeonidis received his BS in Biology from Loyola University in Chicago, and his MA, MPhil and PhD in Cellular, Molecular and Biophysical Studies from Columbia University’s College of Physicians and Surgeons, where he graduated first in his class, worked on the regulation of gene expression through the NF-kB/IkB pathway, and cloned one of the three NF-kB inhibitory genes, IkB epsilon. Dr. Simeonidis completed his postdoctoral fellowship at Harvard Medical School and the Brigham and Women’s Hospital in the laboratory of Dr. Tucker Collins, where he worked on signal transduction pathways in inflammation and atherosclerosis, and has also received his MBA in Healthcare Management at The Wharton School.
